# Identification of Medicinal Products —  Implementation and Use - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/identification-of-medicinal-products-implementation-and-use/389d6672-9c7a-4d0b-8c2f-dfd968df1f09

> FDA guidance document: Identification of Medicinal Products —  Implementation and Use. Issue date: March 30, 2023. Get complete insights and analysis.

---

## Details

- Title: Identification of Medicinal Products —  Implementation and Use
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2023-03-30
- Last Changed: 2023-03-31
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2023-D-0266">FDA-2023-D-0266</a>

## Related Documents

- [Clinical Pharmacology Considerations for Antibody-Drug Conjugates  Guidance for Industry:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-antibody-drug-conjugates-guidance-for-industry-guidance-for-industry/ee3ed09c-6580-489f-bb06-0e93f612d604)
- [Q13 Continuous Manufacturing of Drug Substances and Drug Products:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/q13-continuous-manufacturing-of-drug-substances-and-drug-products-guidance-for-industry/2724500a-92c1-4369-92e2-13983181dbcf)
- [Benefit-Risk Assessment for New Drug and Biological Products](https://www.globalkeysolutions.net/guidances/guidance-document/benefit-risk-assessment-for-new-drug-and-biological-products/90bf84f4-05cf-4617-b13d-bbb345349aed)